| Ytd | 13.29% | |
| 1y | 73.51% |
| Open | 90.61 | Prev Close | 90.38 | Low | 89.82 | High | 91.49 | Mkt Cap | 4.13B |
| Vol | 437.33K | Avg Vol | 863.38K | EPS | 5.01 | P/E | 18.12 | Forward P/E | 15.82 |
| Beta | 0.52 | Short Ratio | 4.59 | Inst. Own | 108.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 78.42 | 200-d Avg | 69.28 | 1yr Est | 96.20 |
HAE News
Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasm
Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's fo
Haemonetics NYSE: HAE reported a stronger start to fiscal 2027, with first-quarter revenue rising 6%
Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the p
JP Morgan analyst Allen Gong maintains Haemonetics (NYSE:HAE) with a Neutral and raises the price
BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price targ
Haemonetics (NYSE:HAE) widens FY2027 sales outlook from $1.410 billion-$1.427 billion to $1.401 bill
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings
On Tuesday, 596 companies set new 52-week highs.
Stocks That Hit 52-Week Lows On Monday